Heinz Läubli
Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours.
Melero I, de Miguel Luken M, de Velasco G, Garralda E, Martin-Liberal J, Jörger M, Alonso G, Goebeler M, Schuler M, König D, Dummer R, Reig M, Rodriguez Ruiz M, Calvo E, Esteban-Villarrubia J, Oberoi A, Sabat P, Soto-Castillo J, Koster K, Saavedra O, Sayehli C, Gromke T, Läubli H, Ramelyte E, Fortuny M, Landa-Magdalena A, Moreno I, Torres-Jiménez J, Hernando-Calvo A, Hess D, Racca F, Richly H, Schmitt A, Eggenschwiler C, Sanduzzi-Zamparelli M, Vilalta-Lacarra A, Trojan J, Koch C, Galle P, Foerster F, Trajanoski Z, Hackl H, Gogolla F, Koll F, Wild P, Chun F, Reis H, Lloyd P, Machacek M, Gajewski T, Fridman W, Eggermont A, Bargou R, Schöniger S, Rüschoff J, Tereshchenko A, Zink C, Dantas-Silva A, Lichtenegger F, Akdemir J, Rüdiger M, L'Huillier P, Dutta A, Haake M, Auckenthaler A, Gjorgjioska A, Rössler B, Hermann F, Liebig M, Reichhardt D, Schuberth-Wagner C, Wischhusen J, Fettes P, Auer M, Klar K, Leo E. Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours. Nature 2024
11.12.2024Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours.
11.12.2024Nature 2024
Melero Ignacio, de Miguel Luken Maria, de Velasco Guillermo, Garralda Elena, Martin-Liberal Juan, Jörger Markus, Alonso Guzman, Goebeler Maria-Elisabeth, Schuler Martin, König David, Dummer Reinhard, Reig Maria, Rodriguez Ruiz Maria-Esperanza, Calvo Emiliano, Esteban-Villarrubia Jorge, Oberoi Arjun, Sabat Paula, Soto-Castillo Juan José, Koster Kira-Lee, Saavedra Omar, Sayehli Cyrus Michael, Gromke Tanja, Läubli Heinz, Ramelyte Egle, Fortuny Marta, Landa-Magdalena Ana, Moreno Irene, Torres-Jiménez Javier, Hernando-Calvo Alberto, Hess Dagmar, Racca Fabricio, Richly Heike, Schmitt Andreas Michael, Eggenschwiler Corinne, Sanduzzi-Zamparelli Marco, Vilalta-Lacarra Anna, Trojan Jörg, Koch Christine, Galle Peter R, Foerster Friedrich, Trajanoski Zlatko, Hackl Hubert, Gogolla Falk, Koll Florestan J, Wild Peter J, Chun Felix Kyoung Hwan, Reis Henning, Lloyd Peter, Machacek Matthias, Gajewski Thomas F, Fridman Wolf H, Eggermont Alexander M M, Bargou Ralf C, Schöniger Sandra, Rüschoff Josef, Tereshchenko Anastasiia, Zink Carina, Dantas-Silva Amanda, Lichtenegger Felix S, Akdemir Julia, Rüdiger Manfred, L'Huillier Phil, Dutta Aradhana, Haake Markus, Auckenthaler Alexandra, Gjorgjioska Ana, Rössler Bernhard, Hermann Frank, Liebig Mara, Reichhardt Daniela, Schuberth-Wagner Christine, Wischhusen Jörg, Fettes Petra, Auer Marlene, Klar Kathrin, Leo Eugen
Autoimmunity Against Surfactant Protein B Is Associated with Pneumonitis During Checkpoint Blockade.
Wyss N, Berner F, Walter V, Jochum A, Purde M, Abdou M, Sinnberg T, Hofmeister K, Pop O, Hasan A, Bauer J, Cheng H, Lütge M, Klümper N, Diem S, Kosaloglu-Yalcin Z, Zhang Y, Sellmer L, Macek B, Karbach J, König D, Läubli H, Zender L, Meyer B, Driessen C, Schürch C, Jochum W, Amaral T, Heinzerling L, Cozzio A, Hegazy A, Schneider T, Brutsche M, Sette A, Lenz T, Walz J, Rammensee H, Früh M, Jäger E, Becher B, Tufman A, Núñez N, Jörger M, Flatz L. Autoimmunity Against Surfactant Protein B Is Associated with Pneumonitis During Checkpoint Blockade. Am J Respir Crit Care Med 2024; 210:919-930.
01.10.2024Autoimmunity Against Surfactant Protein B Is Associated with Pneumonitis During Checkpoint Blockade.
01.10.2024Am J Respir Crit Care Med 2024; 210:919-930
Wyss Nina, Berner Fiamma, Walter Vincent, Jochum Ann-Kristin, Purde Mette T, Abdou Marie-Therese, Sinnberg Tobias, Hofmeister Kathrin, Pop Oltin, Hasan Ali, Bauer Jens, Cheng Hung-Wei, Lütge Mechthild, Klümper Niklas, Diem Stefan, Kosaloglu-Yalcin Zeynep, Zhang Yizheng, Sellmer Laura, Macek Boris, Karbach Julia, König David, Läubli Heinz, Zender Lars, Meyer Britta S, Driessen Christoph, Schürch Christian M, Jochum Wolfram, Amaral Teresa, Heinzerling Lucie M, Cozzio Antonio, Hegazy AhN, Schneider Tino, Brutsche Martin, Sette Alessandro, Lenz Tobias L, Walz Juliane Sarah, Rammensee Hans-Georg, Früh Martin, Jäger Elke, Becher Burkhard, Tufman Amanda, Núñez Nicolás Gonzalo, Jörger Markus, Flatz Lukas
Effects of CTLA-4 Single Nucleotide Polymorphisms on Toxicity of Ipilimumab-Containing Regimens in Patients With Advanced Stage Melanoma.
de Joode K, Mora A, van Schaik R, Zippelius A, van der Veldt A, Gerard C, Läubli H, Michielin O, von Moos R, Jörger M, Levesque M, Aeppli S, Mangana J, Mangas C, Trost N, Meyer S, Parvex S, Mathijssen R, Metaxas Y. Effects of CTLA-4 Single Nucleotide Polymorphisms on Toxicity of Ipilimumab-Containing Regimens in Patients With Advanced Stage Melanoma. J Immunother 2024; 47:190-194.
06.02.2024Effects of CTLA-4 Single Nucleotide Polymorphisms on Toxicity of Ipilimumab-Containing Regimens in Patients With Advanced Stage Melanoma.
06.02.2024J Immunother 2024; 47:190-194
de Joode Karlijn, Mora Alfonso Rojas, van Schaik Ron H N, Zippelius Alfred, van der Veldt Astrid, Gerard Camille Léa, Läubli Heinz, Michielin Olivier, von Moos Roger, Jörger Markus, Levesque Mitchell Paul, Aeppli Stefanie, Mangana Johanna, Mangas Cristina, Trost Nadine, Meyer Stefan, Parvex Sandra Leoni, Mathijssen Ron H J, Metaxas Yannis
A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol.
Mastall M, Roth P, Bink A, Maranta A, Läubli H, Hottinger A, Hundsberger T, Migliorini D, Ochsenbein A, Seystahl K, Imbach L, Hortobágyi T, Held L, Weller M, Wirsching H. A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol. BMC cancer 2024; 24:82.
15.01.2024A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol.
15.01.2024BMC cancer 2024; 24:82
Mastall Maximilian, Roth Patrick, Bink Andrea, Maranta Angela Fischer, Läubli Heinz, Hottinger Andreas Felix, Hundsberger Thomas, Migliorini Denis, Ochsenbein Adrian F, Seystahl Katharina, Imbach Lukas L, Hortobágyi Tibor, Held Leonhard, Weller Michael, Wirsching Hans-Georg
Glioblastoma in the oldest old: Clinical characteristics, therapy, and outcome in patients aged 80 years and older.
Stadler C, Gramatzki D, Le Rhun E, Hottinger A, Hundsberger T, Roelcke U, Läubli H, Hofer S, Seystahl K, Wirsching H, Weller M, Roth P. Glioblastoma in the oldest old: Clinical characteristics, therapy, and outcome in patients aged 80 years and older. Neurooncol Pract 2023; 11:132-141.
20.10.2023Glioblastoma in the oldest old: Clinical characteristics, therapy, and outcome in patients aged 80 years and older.
20.10.2023Neurooncol Pract 2023; 11:132-141
Stadler Christina, Gramatzki Dorothee, Le Rhun Emilie, Hottinger Andreas Felix, Hundsberger Thomas, Roelcke Ulrich, Läubli Heinz, Hofer Silvia, Seystahl Katharina, Wirsching Hans-Georg, Weller Michael, Roth Patrick
Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade.
Berner F, Bomze D, Lichtensteiger C, Walter V, Niederer R, Hasan Ali O, Wyss N, Bauer J, Freudenmann L, Marcu A, Wolfschmitt E, Haen S, Gross T, Abdou M, Diem S, Knöpfli S, Sinnberg T, Hofmeister K, Cheng H, Toma M, Klümper N, Purde M, Pop O, Jochum A, Pascolo S, Jörger M, Früh M, Jochum W, Rammensee H, Läubli H, Hölzel M, Neefjes J, Walz J, Flatz L. Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade. Sci Immunol 2022; 7:eabn9644.
02.09.2022Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade.
02.09.2022Sci Immunol 2022; 7:eabn9644
Berner Fiamma, Bomze David, Lichtensteiger Christa, Walter Vincent, Niederer Rebekka, Hasan Ali Omar, Wyss Nina, Bauer Jens, Freudenmann Lena Katharina, Marcu Ana, Wolfschmitt Eva-Maria, Haen Sebastian, Gross Thorben, Abdou Marie-Therese, Diem Stefan, Knöpfli Stella, Sinnberg Tobias, Hofmeister Kathrin, Cheng Hung-Wei, Toma Marieta, Klümper Niklas, Purde Mette-Triin, Pop Oltin Tiberiu, Jochum Ann-Kristin, Pascolo Steve, Jörger Markus, Früh Martin, Jochum Wolfram, Rammensee Hans-Georg, Läubli Heinz, Hölzel Michael, Neefjes Jacques, Walz Juliane, Flatz Lukas
Effects of COVID-19 Lockdown on Melanoma Diagnosis in Switzerland: Increased Tumor Thickness in Elderly Females and Shift towards Stage IV Melanoma during Lockdown.
Kostner L, Cerminara S, Pamplona G, Maul J, Dummer R, Ramelyte E, Mangana J, Wagner N, Cozzio A, Kreiter S, Kogler A, Streit M, Wysocki A, Zippelius A, Läubli H, Navarini A, Maul L. Effects of COVID-19 Lockdown on Melanoma Diagnosis in Switzerland: Increased Tumor Thickness in Elderly Females and Shift towards Stage IV Melanoma during Lockdown. Cancers (Basel) 2022; 14
10.05.2022Effects of COVID-19 Lockdown on Melanoma Diagnosis in Switzerland: Increased Tumor Thickness in Elderly Females and Shift towards Stage IV Melanoma during Lockdown.
10.05.2022Cancers (Basel) 2022; 14
Kostner Lisa, Cerminara Sara Elisa, Pamplona Gustavo Santo Pedro, Maul Julia-Tatjana, Dummer Reinhard, Ramelyte Egle, Mangana Johanna, Wagner Nikolaus, Cozzio Antonio, Kreiter Saskia, Kogler Angelika, Streit Markus, Wysocki Anja, Zippelius Alfred, Läubli Heinz, Navarini Alexander, Maul Lara Valeska
Fitness-to-drive for glioblastoma patients: Guidance from the Swiss Neuro-Oncology Society (SwissNOS) and the Swiss Society for Legal Medicine (SGRM)
Hofer S, Baumert B, Läubli H, Gramatzki D, Reinert M, Pesce G, Schucht P, Frank I, Lehnick D, Weiss T, Wirsching H, Wolpert F, Roth P, Eggenberger N, Pflugshaupt T, Keller K, Imbach L, Roelcke U, Hutter G, Hundsberger T, Hertler C, Le Rhun E, Vasella F, Cordier D, Neidert M, Hottinger A, Migliorini D, Weller M. Fitness-to-drive for glioblastoma patients: Guidance from the Swiss Neuro-Oncology Society (SwissNOS) and the Swiss Society for Legal Medicine (SGRM). Swiss Med Wkly 2021; 151:w20501.
16.05.2021Fitness-to-drive for glioblastoma patients: Guidance from the Swiss Neuro-Oncology Society (SwissNOS) and the Swiss Society for Legal Medicine (SGRM)
16.05.2021Swiss Med Wkly 2021; 151:w20501
Hofer Silvia, Baumert Brigitta, Läubli Heinz, Gramatzki Dorothee, Reinert Michael, Pesce Gianfranco, Schucht Philippe, Frank Irène, Lehnick Dirk, Weiss Tobias, Wirsching Hans-Georg, Wolpert Fabian, Roth Patrick, Eggenberger Noemi, Pflugshaupt Tobias, Keller Kristina, Imbach Lukas, Roelcke Ulrich, Hutter Gregor, Hundsberger Thomas, Hertler Caroline, Le Rhun Emilie, Vasella Flavio, Cordier Dominik, Neidert Marian Christoph, Hottinger Andreas, Migliorini Denis, Weller Michael
A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adults
Roth P, Hofer S, Pesce G, Roelcke U, Mamot C, Reinert M, Schucht P, Läubli H, Hundsberger T, Hottinger A, Weller M. A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adults. Swiss Med Wkly 2020; 150:w20256.
18.06.2020A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adults
18.06.2020Swiss Med Wkly 2020; 150:w20256
Roth Patrick, Hofer Silvia, Pesce Gianfranco, Roelcke Ulrich, Mamot Christoph, Reinert Michael, Schucht Philippe, Läubli Heinz, Hundsberger Thomas, Hottinger Andreas F, Weller Michael
Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer
Berner F, Hartmann F, Cheng H, Hönger G, Recher M, Goldman J, Cozzio A, Früh M, Neefjes J, Driessen C, Ludewig B, Hegazy A, Jochum W, Speiser D, Zippelius A, Läubli H, Bomze D, Diem S, Ali O, Fässler M, Ring S, Niederer R, Ackermann C, Baumgaertner P, Pikor N, Cruz C, van de Veen W, Akdis M, Nikolaev S, Flatz L. Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer. JAMA Oncol 2019; 5:1043-1047.
01.07.2019Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer
01.07.2019JAMA Oncol 2019; 5:1043-1047
Berner Fiamma, Hartmann Fabienne, Cheng Hung-Wei, Hönger Gideon, Recher Mike, Goldman Jonathan, Cozzio Antonio, Früh Martin, Neefjes Jacques, Driessen Christoph, Ludewig Burkhard, Hegazy Ahmed N, Jochum Wolfram, Speiser Daniel E, Zippelius Alfred, Läubli Heinz, Bomze David, Diem Stefan, Ali Omar Hasan, Fässler Mirjam, Ring Sandra, Niederer Rebekka, Ackermann Christoph J, Baumgaertner Petra, Pikor Natalia, Cruz Cristina Gil, van de Veen Willem, Akdis Mübeccel, Nikolaev Sergey, Flatz Lukas
A Variant of a Killer Cell Immunoglobulin-like Receptor Is Associated with Resistance to PD-1 Blockade in Lung Cancer
Trefny M, Savic S, Jermann P, Alborelli I, Schaub S, Stenner F, Früh M, Trajanoski Z, Flatz L, Mertz K, Zippelius A, Geier F, Thommen D, Rothschild S, Uhlenbrock F, Rieder D, Kasenda B, Stanczak M, Berner F, Kashyap A, Kaiser M, Herzig P, Poechtrager S, Läubli H. A Variant of a Killer Cell Immunoglobulin-like Receptor Is Associated with Resistance to PD-1 Blockade in Lung Cancer. Clin Cancer Res 2019; 25:3026-3034.
14.02.2019A Variant of a Killer Cell Immunoglobulin-like Receptor Is Associated with Resistance to PD-1 Blockade in Lung Cancer
14.02.2019Clin Cancer Res 2019; 25:3026-3034
Trefny Marcel P, Savic Spasenija, Jermann Philip, Alborelli Ilaria, Schaub Stefan, Stenner Frank, Früh Martin, Trajanoski Zlatko, Flatz Lukas, Mertz Kirsten D, Zippelius Alfred, Geier Florian, Thommen Daniela S, Rothschild Sacha I, Uhlenbrock Franziska, Rieder Dietmar, Kasenda Benjamin, Stanczak Michal A, Berner Fiamma, Kashyap Abhishek S, Kaiser Monika, Herzig Petra, Poechtrager Severin, Läubli Heinz